In a report released yesterday, Peter Lawson from Barclays maintained a Buy rating on Exelixis (EXEL – Research Report). The company’s shares opened today at $17.00.
Lawson covers the Healthcare sector, focusing on stocks such as Blueprint Medicines, Immunocore Holdings, and ImmunoGen. According to TipRanks, Lawson has an average return of 0.8% and a 42.07% success rate on recommended stocks.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Exelixis with a $26.09 average price target, which is a 53.47% upside from current levels. In a report released today, JMP Securities also maintained a Buy rating on the stock with a $24.00 price target.
See today’s best-performing stocks on TipRanks >>
The company has a one-year high of $23.40 and a one-year low of $14.87. Currently, Exelixis has an average volume of 2.31M.
Based on the recent corporate insider activity of 59 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of EXEL in relation to earlier this year. Most recently, in December 2022, George Poste, a Director at EXEL sold 40,000.00 shares for a total of $667,200.00.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Exelixis, Inc. is a biopharmaceutical company, which engages in the development, commercialization, and discovery of new medicines for the treatment of cancer. It offers products under the brands of Cometriq, Cabometyx, and Cotellic. The company was founded by Corey S. Goodman and Stelios B. Papadopoulos on November 15, 1994 and is headquartered in Alameda, CA.
Read More on EXEL:
- Credit Suisse Says These 2 Stocks Could Surge Over 30% From Current Levels
- Credit Suisse bullish on Exelixis, initiates with an Outperform
- Exelixis initiated with an Outperform at Credit Suisse
- William Blair says Exelixis cabozantinib patent verdict in line with expectation
- Court Rulings Bring Good and Bad News for Exelixis (NASDAQ:EXEL)
